Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background Time to clinical worsening has been proposed as a primary end point in clinical trials of pulmonary arterial hypertension (PAH); however, neither standardized nor validated definitions of clinical worsening across PAH trials exist. This study aims to evaluate a proposed definition of clinical worsening within a large prospective, observational registry of patients with PAH with respect to its value as a predictor of proximate (within 1 year) risk for subsequent major events (ie, death, transplantation, or atrial septostomy). Methods We assessed overall 2-year survival and survival free from major events to determine the relationship between clinical worsening and major events among adults with hemodynamically defined PAH (N = 3,001). Freedom from clinical worsening was defined as freedom from worsening functional class (FC), a ≥ 15% reduction in 6-min walk distance (6MWD), all-cause hospitalization, or the introduction of parenteral prostacyclin analog therapy. Results In the 2 years of follow-up, 583 patients died. Four hundred twenty-six died after a documented clinical worsening event, including FC worsening (n = 128), a ≥ 15% reduction in 6MWD (n = 118), all-cause hospitalization (n = 370), or introduction of a prostacyclin analog (n = 91). Patients who experienced clinical worsening had significantly poorer subsequent 1-year survival postworsening than patients who did not worsen (P Conclusions Clinical worsening was highly predictive of subsequent proximate m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [287]
In the citing paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [287]
Citations
Cites
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Self-citationPrimary Pulmonary Hypertension: A National Prospective Study
RICH, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., DETRE, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,039
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Self-citationLong-term intravenous epoprostenol infusion in primary pulmonary hypertension
Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Hervé, P., Rainisio, M., & Simonneau, G. É. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02012-0 · Cited by 1,383
Pulmonary Arterial Hypertension
Badesch, D. B., Raskob, G. E., Elliott, C. G., Krichman, A. M., Farber, H. W., Frost, A. E., Barst, R. J., Benza, R. L., Liou, T. G., Turner, M., et al. (2010) · Chest · doi:10.1378/chest.09-1140 · Cited by 1,178
Self-citationMedical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Self-citationSurvival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
Humbert, M., Sitbon, O., Yaïci, A., Montani, D., O'Callaghan, D. S., Jaïs, X., Parent, F., Savale, L., Natali, D., Günther, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00057010 · Cited by 674
Analysing Survival Data From Clinical Trials and Observational Studies
(1996) · Technometrics · doi:10.1080/00401706.1996.10484530 · Cited by 663
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Predicting Survival in Patients With Pulmonary Arterial Hypertension
Benza, R. L., Gomberg-Maitland, M., Elliott, C. G., Farber, H. W., Foreman, A. J., Frost, A. E., McGoon, M. D., Pasta, D. J., Selej, M., Burger, C. D., et al. (2019) · Chest · doi:10.1016/j.chest.2019.02.004 · Cited by 643
“0 predicted clinical worsening, which is defined as subsequent all-cause hospitalization or initiation of parenteral prostacyclin therapy for any reason.(24) In contrast to the definition from Frost et al,(24) New York Heart Association/WHO functional class (FC) and 6-min walk distance (6MWD) were not included in the…”
MethodSelf-citationCombination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis
Lajoie, A. C., Lauzière, G., Lega, J.-C., Lacasse, Y., Martin, S., Simard, S., Bonnet, S., & Provencher, S. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00027-8 · Cited by 235
Clinical trial design and new therapies for pulmonary arterial hypertension
Sitbon, O., Gomberg-Maitland, M., Granton, J., Lewis, M. I., Mathai, S. C., Rainisio, M., Stockbridge, N. L., Wilkins, M. R., Zamanian, R. T., & Rubin, L. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.01908-2018 · Cited by 196
Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension
Alabed, S., Shahin, Y., Garg, P., Alandejani, F., Johns, C., Lewis, R. A., Condliffe, R. A., Wild, J. M., Kiely, D. G., & Swift, A. J. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.08.013 · Cited by 164
Exercise-based rehabilitation programmes for pulmonary hypertension
Morris, N. R., Kermeen, F. D., & Holland, A. E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011285.pub2 · Cited by 162
Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance
Farber, H. W., Miller, D. P., McGoon, M. D., Frost, A. E., Benton, W. W., & Benza, R. L. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.08.020 · Cited by 133
Self-citationPulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
McLaughlin, V. V., Hoeper, M. M., Channick, R. N., Chin, K., Delcroix, M., Gaine, S., Ghofrani, H. A., Jansa, P., Lang, I. M., Mehta, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.010 · Cited by 118
Emmons‐Bell, S., Johnson, C. O., Boon-Dooley, A. S., Corris, P. A., Leary, P. J., Rich, S., Yacoub, M. H., & Roth, G. A. (2021) · Pulmonary Circulation · doi:10.1002/pul2.12020 · Cited by 109
Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update
Coons, J. C., Pogue, K. T., Kolodziej, A., Hirsch, G. A., & George, M. P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1235-4 · Cited by 98
Burger, C. D., Long, P. K., Shah, M. R., McGoon, M. D., Miller, D. P., Romero, A., Benton, W. W., & Safford, R. E. (2014) · CHEST Journal · doi:10.1378/chest.14-0193 · Cited by 98
Self-citationExercise-based rehabilitation programmes for pulmonary hypertension
Morris, N. R., Kermeen, F. D., Jones, A. W., Lee, J. Y. T., & Holland, A. E. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011285.pub3 · Cited by 84
The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry
Zelniker, T. A., Huscher, D., Noordegraaf, A. V., Ewert, R., Lange, T. J., Klose, H. F. E., Dumitrescu, D., Halank, M., Held, M., Gall, H. J., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1207-5 · Cited by 72
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
Lajoie, A., Bonnet, S., & Provencher, S. (2017) · Pulmonary Circulation · doi:10.1177/2045893217710639 · Cited by 58
“Another alternative trial would be to include a greater proportion of patients who are clinically deteriorating since it is known that patients who recently had an event of clinical worsening are at higher risk of mortality.(42) This is a concept largely used in clinical trials in heart failure and idiopathic pulmonar…”
BackgroundTsutsumi, T., Nagaoka, T., Yoshida, T., Wang, L., Kuriyama, S., Suzuki, Y., Nagata, Y., Harada, N., Kodama, Y., Takahashi, F., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214697 · Cited by 55
Frantz, R. P., Schilz, R. J., Chakinala, M. M., Badesch, D. B., Frost, A., McLaughlin, V. V., Barst, R. J., Rosenberg, D., Miller, D. P., Hartline, B. K., et al. (2014) · CHEST Journal · doi:10.1378/chest.14-1004 · Cited by 49
Self-citationMcLaughlin, V. V., Channick, R. N., Marco, T. D., Farber, H. W., Gaine, S., Galiè, N., Krasuski, R. A., Preston, I. R., Souza, R., Coghlan, G., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.10.043 · Cited by 47
Self-citationReinders, S., Didden, E., & Ong, R. C.-Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02994-w · Cited by 38
“Ten studies were included that reported morbidity or QoL outcomes for adult PAH, based on 15 individual reports as three studies covered multiple reports on relevant outcomes (Swedish National PH Registry [42, 43], REVEAL registry [20, 44–46], and Japan PH Registry [47, 48]) (See Table S3).”
BackgroundExercise-based rehabilitation programmes for pulmonary hypertension
Morris, N. R., Kermeen, F. D., & Holland, A. E. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011285 · Cited by 37
Frantz, R. P., Hill, J. W., Lickert, C. A., Wade, R. L., Cole, M. R., Tsang, Y., & Drake, W. (2019) · Pulmonary Circulation · doi:10.1177/2045894019880086 · Cited by 36
Guo, X., Lai, J., Wang, H., Tian, Z., Wang, Q., Zhao, J., Li, M., Fang, Q., Fang, L., Liu, Y., et al. (2019) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jez311 · Cited by 36
Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension
Ploegstra, M., Arjaans, S., Zijlstra, W. M. H., Douwes, J. M., Vissia-Kazemier, T. R., Roofthooft, M. T. R., Hillege, H. L., & Berger, R. M. F. (2015) · CHEST Journal · doi:10.1378/chest.14-3066 · Cited by 35
Kanwar, M. K., Raina, A., Lohmueller, L. C., Kraisangka, J., & Benza, R. L. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0950-y · Cited by 33
Self-citationAssessing risk in pulmonary arterial hypertension: what we know, what we don't
Benza, R. L., Farber, H. W., Selej, M., & Gomberg‐Maitland, M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01353-2017 · Cited by 31
Self-citationHarder, E. M., Small, A., & Fares, W. H. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.105850 · Cited by 25
Tremblay, É., Gosselin, C., Mai, V., Lajoie, A. C., Kilo, R., Weatherald, J. C., Lacasse, Y., Bonnet, S., Lega, J., & Provencher, S. (2022) · Circulation · doi:10.1161/circulationaha.121.058635 · Cited by 24
“The frequencies of occurrence of each traditional component of the CW composite end point were assessed, including (1) allcause mortality, (2) PAH-related hospitalization, (3) transplantation, (4) atrial septostomy, (5) treatment escalation, and (6) symptomatic progression (frequently reported as PAH worsening).”
MethodWilson, M. A., Keeley, J. H., Kingman, M. S., Wang, J., & Rogers, F. (2020) · Pulmonary Circulation · doi:10.1177/2045894020950186 · Cited by 23
Divers, C., Platt, D. M., Wang, E., Lin, J., Lingohr-Smith, M., & Mathai, S. C. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.1.92 · Cited by 22
Breathing (and Coding?) a Bit Easier
Mathai, S. C., & Mathew, S. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.04.004 · Cited by 19
Lung transplantation: an overview of candidacy and outcomes.
Rampolla, R. E. (2014) · PubMed · Cited by 17
Wang, L., Chen, X., Wan, K., Gong, C., Li, W., Xu, Y., Wang, J., He, J., Wen, B., Han, Y., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019899778 · Cited by 16
Clinical application of risk assessment in PAH: Expert center APRN recommendations
Wilson, M. A., Keeley, J. H., Kingman, M. S., McDevitt, S., Brewer, J., Rogers, F., Hill, W., Rideman, Z., & Broderick, M. J. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12106 · Cited by 15
Huang, J. H. Y., Mehta, S., & Mura, M. (2015) · Respiration · doi:10.1159/000370124 · Cited by 15
Beghetti, M., Brand, M., Berger, R. M. F., Humpl, T., Wheeler, J. G., Ivy, D. D., & Bonnet, D. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.04.062 · Cited by 15
McGregor, G., Bruce, J., Ennis, S., Mason, J. M., Lall, R., Ji, C., Sandhu, H. K., Seers, K., Banerjee, P., Canaway, A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01182-y · Cited by 14
Perioperative Right Ventricular Dysfunction: Analysis of Outcomes
Subramani, S., Sharma, A., Arora, L. L., Hanada, S., Krishnan, S., & Ramakrishna, H. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.01.032 · Cited by 14
Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it
Benza, R. L., Lohmueller, L. C., Kraisangka, J., & Kanwar, M. K. (2018) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-16.3.125 · Cited by 14
Self-citationRisk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?
Farber, H. W., & Benza, R. L. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201801-0042ed · Cited by 13
Self-citationWilson, M. A., Anguiano, R. H., Awdish, R., Coons, J. C., Kimber, A., Morrison, M. A., Paulus, S., Schmit, A., Spexarth, F. C., Swetz, K. M., et al. (2021) · Pulmonary Circulation · doi:10.1002/pul2.12003 · Cited by 12
Guo, X., Lai, J., Wang, H., Tian, Z., Zhao, J., Li, M., Fang, Q., Fang, L., Liu, Y., & Zeng, X. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15682 · Cited by 12
Evaluating suspected pulmonary hypertension: A structured approach
Bhatnagar, A., Wiesen, J., Dweik, R. A., & Chaisson, N. F. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17065 · Cited by 12
Gaining insights into pulmonary hypertension in respiratory diseases
Barberà, J. A., & Blanco, I. (2015) · European Respiratory Journal · doi:10.1183/13993003.01288-2015 · Cited by 12
Chakinala, M. M., & Barst, R. J. (2013) · Pulmonary Circulation · doi:10.1086/674456 · Cited by 10
Demerouti, E., Karyofyllis, P., Manginas, A., Anthi, A., Karatasakis, G., Athanassopoulos, G. D., & Voudris, V. V. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00319-z · Cited by 9
The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia
Morrisroe, K., Stevens, W., Sahhar, J., Ngian, G., Ferdowsi, N., Hansen, D., Patel, S., Hill, C. L., Roddy, J., Walker, J. G., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0989-1 · Cited by 9
“The association of hospitalization and increased risk of death has been reported previously in PAH patients [24] and has been recently included as a variable in the updated REVEAL risk score calculator used to predict clinical worsening and survival in PAH patients [25].”
MethodPatients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy
Mai, V., Gosselin, C., Tremblay, É., Rompré, G., Lajoie, A. C., Weatherald, J. C., Lega, J., Bonnet, S., & Provencher, S. (2023) · Thorax · doi:10.1136/thorax-2022-219490 · Cited by 9
McConnell, J. W., Tsang, Y., Pruett, J., & Drake, W. B. (2020) · Pulmonary Circulation · doi:10.1177/2045894020911831 · Cited by 9
Use of Oral Anticoagulant Drugs in Patients with Pulmonary Hypertension
Rodríguez, P. D., Valle, F. G., & Proietti, M. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.08.018 · Cited by 8
Morris, N. R., Louis, M., Strugnell, W., Harris, J., Lin, A., Feenstra, J., & Seale, H. E. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0586-8 · Cited by 8
Oba, Y., Maduke, T., Fakhouri, E. W., & Goite, Y. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015824.pub2 · Cited by 7
Update on pulmonary arterial hypertension research: proceedings from a meeting of experts
McLaughlin, V. V., Bacchetta, M. D., Badesch, D. B., Benza, R. L., Burger, C. D., Chin, K., Frantz, R. P., Frost, A., Hemnes, A. R., Kim, N. H., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1404974 · Cited by 7
Self-citationMartynyuk, T. V., Aleevskaya, A. M., Rodnenkov, O. V., Zorin, A. V., Михайловна, К. А., Наконечников, С. Н., & Chazova, I. E. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-54-60 · Cited by 7
Pulmonary Hypertension and Palliative Care: What, When, Where, and Why?
Fenstad, E. R., Wordingham, S. E., & Swetz, K. M. (2016) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x.15.1.26 · Cited by 7
Association between splenectomy and portal hypertension in the development of pulmonary hypertension
Huang, L., Li, W., Yang, T., Xiong, C., Ni, X., Gu, Q., & He, J. (2019) · Pulmonary Circulation · doi:10.1177/2045894019895426 · Cited by 7
Gauthier‐Loiselle, M., Tsang, Y., Lefèbvre, P., Agron, P., Royer, J., Lynum, K. S. B., Bennett, L., & Panjabi, S. S. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049162 · Cited by 6
Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension
Zhang, C., Tsang, Y., He, J., & Panjabi, S. S. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02501-5 · Cited by 6
Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension
Clarke, M. M., Walter, C. E., Agarwal, R., Kanwar, M. K., & Benza, R. L. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.919849 · Cited by 6
“Despite lack of mortality benefit, the improved outcomes with macitentan are important for several reasons: worsening PAH, defined as multiple non-fatal components, has been shown to be a powerful and valid end point for guiding treatment escalation and for predicting proximate mortality; hospitalizations for PAH, whi…”
BackgroundSelf-citationLi, W., Yang, T., Zhang, Y., Gu, Q., Liu, Z., Ni, X., Luo, Q., Xiong, C., & He, J. (2016) · Respirology · doi:10.1111/resp.12861 · Cited by 5
Beast of Pulmonary Arterial Hypertension Burden
Mathai, S. C., & McLaughlin, V. V. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3829 · Cited by 5
Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension
Lajoie, A. C., Guay, C.-A., Lega, J., Lauzière, G., Simard, S., Lambert, C., Lacasse, Y., Bonnet, S., & Provencher, S. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.11.014 · Cited by 5
“[ 1 5 3 # 5 CHE ST MA Y 2 0 1 8 ] Pulmonary arterial hypertension (PAH, group 1 of the clinical classification) is a life-threatening disease characterized by a progressive increase in pulmonary vascular resistance, ultimately leading to right heart failure and death.1,2 Throughout the last 20 years, numerous specific…”
BackgroundInfluentialMartynyuk, T. V., & Chazova, I. E. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.09.201013 · Cited by 5
“У ряда пациентов, несмотря на лечение, отмечается прогрессирование ЛАГ с потребностью в повторных госпитализациях по причине декомпенсации кровообращения по большому кругу [10, 11].”
Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review
Burger, C. D., Tsang, Y., Chivers, M., Vekaria, R., Doad, G., Atkins, N., & Panjabi, S. S. (2024) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s460912 · Cited by 4
“10,11 14 The FDA-approved indication for selexipag is for treatment of PAH (World Health Organization [WHO] Group 1) to delay disease progression and reduce the risk of hospitalization.”
BackgroundZhu, Y., Xu, K., Jia, H., Liu, W., Sun, X., Wang, Q., Xu, Y., & Zhu, Y. (2025) · European Journal of Radiology Open · doi:10.1016/j.ejro.2025.100700 · Cited by 3
“…deterioration events, including all-cause mortality, worsening of World Health Organization functional class, a decrease of ≥ 15 % in the six-minute walk test distance, hospitalization due to heart failure or worsening of CTD-PAH, or the initiation of parenteral prostacyclin analog therapy [14].”
Qi, Y., Liang, J., Ma, K., Hu, X. Y., Zhang, Y., Han, X., Xu, D., Zhang, X., Cui, X., Xiang, M., et al. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70099 · Cited by 3
Zhang, Y., Wang, X., Sun, X., Zhou, Z., Li, D., Zhang, Y., Hu, Q., Shan, L., Dai, J., Ye, H., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf140 · Cited by 3
Corrêa, R. D. A., Rezende, C. F., Mancuzo, E. V., Mickael, C. S., Loureiro, C. M. C., Oliveira, R. K. F., Hilton, J. F., & Graham, B. B. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70086 · Cited by 3
A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertension
Amin, A., Mohamadifar, A., Keshmiri, M. S., Ghadrdoost, B., Taghavi, S., & Naderi, N. (2016) · Journal of Critical Care · doi:10.1016/j.jcrc.2016.12.002 · Cited by 3
Pulmonary Arterial Hypertension
Thenappan, T., & Duprez, D. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-14556-3_22 · Cited by 2
Paoli, C. J., Zhang, C. Z., Tang, X., Panjabi, S. S., Thompson, A., & El‐Kersh, K. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108112 · Cited by 2
Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators
Shmalts, A. A. (2022) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2022-06-09 · Cited by 2
Haarman, M. G., & Berger, R. M. F. (2023) · Springer eBooks · doi:10.1007/978-3-030-42937-9_92-1 · Cited by 2
Tharwani, A., Minai, O. A., Rao, Y., Kim, H., & Heresi, G. A. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107919 · Cited by 2
The Road Toward Precision in PH: Personal Omics, Phenomics, and Wearables—Oh My!
Elinoff, J. M., & Solomon, M. A. (2018) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-17.4.141 · Cited by 2
Pulmonary arterial hypertension: challenges and achievements 2021
Rezukhina, E. A., Martynyuk, T. V., Солтановна, В. З., Владимирович, Г. В., & Чазова, И. Е. (2022) · Eurasian heart journal · doi:10.38109/2225-1685-2022-1-80-89 · Cited by 2
Kiyota, T. A., Mendes, P., & Pereira, M. C. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2601388 · Cited by 1
Biomarkers and Other Methods for Assessing Patient Progress
Al‐Naamani, N., & Preston, I. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_14 · Cited by 1
A Contemporary Approach to Pulmonary Arterial Hypertension
Krishnan, U., & Horn, E. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0608-z · Cited by 1
Saha, S. K. (2016) · Archives of Cardiovascular Imaging · doi:10.5812/acvi.41818 · Cited by 1
PH Professional Network: Bridging the Gap: A Multidisciplinary Approach to Transitions of Care
McDevitt, S., & Walter, C. E. (2019) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-18.3.103 · Cited by 1
Hipertensión Pulmonar: estratificación de riesgo. Impacto de su reducción en el pronóstico
Gregorietti, V. (2021) · Revista de la Federación Argentina de Cardiología · doi:10.63600/e1dwj907 · Cited by 1
Expert provider survey of longitudinal assessment in patients with pulmonary arterial hypertension
Kingrey, J. F., Zhou, C. Y., Dalal, B., & Elwing, J. (2022) · Heart & Lung · doi:10.1016/j.hrtlng.2022.10.016 · Cited by 1
The Future of Pulmonary Hypertension
Frantz, R. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_23
Sl, C., Zhang, H., Xie, D. J., Ff, Z., Zhou, L., & Zhang, J. (2016) · International Journal of Cardiology and Research · doi:10.19070/2470-4563-1600012
“PAP, RAP and PVR were the three most important parameters correlated with the prognosis of the PAH patients [1, 16].”
BackgroundTreatment of pulmonary arterial hypertension: an update
Prella, M., Yerly, P., & Aubert, J. (2014) · Cardiovascular Medicine · doi:10.4414/cvm.2014.00276
Risk Stratification—What's My Risk? A Practitioner's Tool
Preston, I. R. (2019) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-18.3.84
Zhang, Y., Zhang, N., Sun, X., Liu, Q., Yuan, X., Wang, Q., & Zhou, L. (2022) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000643
Pediatric Pulmonary Hypertension
Haarman, M. G., & Berger, R. M. F. (2023) · Springer eBooks · doi:10.1007/978-3-030-42937-9_92-2
Pediatric Pulmonary Hypertension
Haarman, M. G., & Berger, R. M. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-07563-6_92
Ahmed, M. K., Tohamy, A. M., Ali, M. A. S., Seedik, M. I., & Wafy, S. M. (2024) · Egyptian Journal of Bronchology · doi:10.1186/s43168-024-00359-x
Costa, G. O. S. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Gao, S., Chen, X., Zhang, C., Mingli, S., & Han, J. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080781
Kimuro, K., Masaki, K., Hirose, M., Inami, T., Taniguchi, Y., Adachi, S., Hosokawa, K., Yamashita, J., Satoh, T., Nakamura, J., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.08.044
Metadata
- Authors
- Frost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D.
- Affiliations
- Baylor College of Medicine (US)
- University of Colorado Denver (US)
- Allegheny General Hospital (US)
- Actelion (United States) (US)
- Mayo Clinic (US)
- Corresponding author
- Frost, Adaani E.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 144
- Issue
- 5
- Pages
- 1521-1529
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2085328300
- Semantic Scholar
- 03ce7f931507745cca05f0abadd9ff31e2c49cb4
- Cited by
- 90
- References
- 30
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 6 · 2019: 15 · 2018: 10 · 2017: 5 · 2016: 8 · 2015: 6 · 2014: 7 · 2013: 1
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- CHEST Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer
- Biogen
- United Therapeutics Corporation
- IC Design Education Center
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- pulmonary arterial hypertension, clinical deterioration, primary endpoint, survival, mortality, functional class, 6-minute walk distance, hospitalization, lung transplantation, atrial septostomy, clinical trial endpoints
- MeSH terms
- Antihypertensive Agents, Exercise Test, Female, Follow-Up Studies, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prognosis, Prospective Studies, Epoprostenol, Registries, Time Factors, United States, Survival Rate, Disease Progression, Disease Management, Familial Primary Pulmonary Hypertension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.